On-demand webcast of expert faculty presentation and case discussion on the potential of antibody drug conjugates that target HER2, HER3, and TROP-2 to optimize treatment outcomes of patients with non-small-cell lung cancer.
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/targeted-adcs-in-nsclc/18192-27245
- Start Date: 2024-02-05 06:00:00
- End Date: 2024-02-05 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 50000.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 50000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest